FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
30.94
+1.58 (+5.38%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close29.36
Open29.36
Bid0.00 x 800
Ask0.00 x 1300
Day's Range29.20 - 31.00
52 Week Range12.59 - 31.00
Volume874,949
Avg. Volume1,015,325
Market Cap2.339B
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateNov 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Feb. 07, 2020 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Steven Cohen Renews His Interest in Verastem
    GuruFocus.com

    Steven Cohen Renews His Interest in Verastem

    Guru invests in restructuring cancer drug developer Continue reading...

  • Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain
    Simply Wall St.

    Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...

  • GlobeNewswire

    Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its second Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel CD16 Fc receptor. This is the Company’s fourth IND from its proprietary iPSC product platform cleared by the FDA, and enables the clinical investigation of FT516 in combination with monoclonal antibody (mAb) therapy across a broad range of solid tumors.

  • InvestorPlace

    3 Top Drug Stocks to Own In 2020

    Broadly speaking, drug stocks have been some of the strongest performing names in the latter part of 2019.Since October 2019, the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has rallied from a low of $96 to nearly $124. The SPDR S&P Biotech ETF (NYSE:XBI) exploded from $75 to a high of $98.79. Even ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) popped from a low of $41 to a high of nearly $65.All despite concerns over potential changes to drug pricing policies with elections ahead.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"While we get the sense that biotech investors are cautious into 2020 with the election and broader macro concerns, we believe that macro issues are unlikely to have material fundamental impact," says Credit Suisse's Evan Seigerman.Wedbush analysts argue, "The fundamentals of the sector look strong. Biotech surged in the third quarter, approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years."Plus, one of the biggest catalysts for future growth are the millions of retiring baby boomers.We're also seeing new, innovative treatments for a myriad of issues. In addition, such stocks are recession-proof because folks will always require medical attention. * 10 2019 Winners That Will Be 2020 Losers Here are three of the top biotech stocks to watch in the New Year. Top Drug Stocks: Fate Therapeutics (FATE)After struggling out the gate, Fate Therapeutics (NASDAQ:FATE) exploded from a low of $14 to $20 a share after posting positive trial results from its natural kill (NK) cell product candidate.With regards to data from its natural killer (NK) cell product candidate, "Current patient- and donor-specific CAR T-cell immunotherapies recognize only one antigen and fail to address the significant risk of relapse due to antigen escape. FT596 is ground-breaking in that it is designed to be available off-the-shelf for timely patient access and to promote deeper and more durable responses by targeting multiple tumor-associated antigens," said Bob Valamehr, Ph.D., Chief Development Officer of Fate Therapeutics.The company's other natural cell killer was also found to kill off cancer in a patient with acute myeloid leukemia (AML). Wells Fargo recently upgraded the FATE stock to an overweight rating with a target of $24. Axsome Therapeutics (AXSM)Axsome Therapeutics (NASDAQ:AXSM) had an explosive year. Since January 2019, AXSM stock exploded from a low of $2.64 to a recent high of $105.55. All after a series of major announcements, throughout the year. In January, for example, AXSM noted that its lead drug candidate, AXS-05 met its primary endpoint in a Phase II trial for major depressive disorder.Two months later, AXSM won FDA Breakthrough Therapy for the drug. By April, the drug also achieved its primary endpoint for smoking cessation. By December, its AXS-12 drug met its primary endpoint in a Phase II trial targeting narcolepsy.Then just two weeks ago, the AXSM stock ramped higher on news of positive late-state results for AXS-05, as a treatment of major depressive disorder. * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever "Given the documented medical need for more potent MDD therapies, and the fact that a whopping 17 million American adults suffer from this condition every year, according to the National Institutes of Health, this experimental depression med has a clear path toward blockbuster status," noted Motley Fool contributor George Budwell. Pfizer (PFE)Last year wasn't kind to Pfizer (NYSE:PFE) or its shareholders. In late July, PFE plunged 21% on company plans to combine its blockbuster drug-selling unit with Mylan (NYSE:MYL), and announced it was cutting its sales and adjusted earnings forecast.However, with a strong drug portfolio, acquisitions, and an undervalued stock, PFE is attracting interest once again. The company also just raised its dividend by 5.6%, which brings the new quarterly dividend to 38 cents from 36 cents payable March 6, 2020 to shareholders as of Jan. 31.Plus, "the valuation on new Pfizer looks appealing, given management's expectation of 6% annualized sales growth through 2025, which could produce 10%-plus yearly gains in earnings per share. New Pfizer has important patent-protected drugs like Ibrance for breast cancer and the pneumonia vaccine Prevnar, plus a strong pipeline," notes Barron's contributor Andrew Bary.As of this writing, Ian Cooper did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Winners That Will Be 2020 Losers * 5-Year Returns for 5 Dow Jones Stocks Entering 2020 * 5 Semiconductor Stocks to Buy for Big Gains In 2020 The post 3 Top Drug Stocks to Own In 2020 appeared first on InvestorPlace.

  • Thomson Reuters StreetEvents

    Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Fate Therapeutics Inc Earnings Call

  • Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
    Zacks

    Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

    The biotech sector witnesses pipeline updates from the annual ASH meet.

  • GlobeNewswire

    Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida. FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D. The Company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.

  • Fate (FATE) Announces Encouraging Data on Immunotherapies
    Zacks

    Fate (FATE) Announces Encouraging Data on Immunotherapies

    Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

  • Company News for Dec 10, 2019
    Zacks

    Company News for Dec 10, 2019

    Companies in the news are: ARQL, THOR, CGC, FATE

  • Here Are The Winners From The Year's Biggest Hematology Meeting
    Investor's Business Daily

    Here Are The Winners From The Year's Biggest Hematology Meeting

    Shares of biotech companies rocketed Monday, led by Forty Seven and Fate, after bullish presentations for cancer and blood-disease drugs at the American Society of Hematology meeting.

  • Benzinga

    Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

    Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE ) FT500 and FT516 therapies were well received by both clinicians ...

  • MarketWatch

    Fate Therapeutics' stock rises on early-stage cancer drug data

    Shares of Fate Therapeutics gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in a very small Phase 1 trial as treatments for acute myeloid leukemia and as a combination therapy for advanced B-cell lymphoma. Separately, Fate said preclinical data for FT596 was also positive, and it will begin enrolling patients in its first human trial early next year. Fate's stock is up 46% year-to-date. The S&P has gained 25% during the same timeframe.

  • Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)

    Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]

  • GlobeNewswire

    Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT596, its off-the-shelf, multi-antigen targeting natural killer (NK) cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line. The data were featured during the 61st American Society of Hematology (ASH) Meeting and Exposition as part of the organization’s CAR-T and Beyond press program, which spotlighted promising next-generation cancer immunotherapies having the potential to overcome the key limitations of patient-specific chimeric antigen receptor (CAR) T-cell therapy.

  • GlobeNewswire

    Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced initial clinical data for its FT516 and FT500 off-the-shelf, iPSC-derived natural killer (NK) cell product candidates. “The safety, tolerability, and immunogenicity data from the Phase 1 dose-escalation stage of FT500, the first-ever cell therapy derived from a clonal master induced pluripotent stem cell line to undergo clinical investigation in the U.S., provide compelling evidence that multiple doses of iPSC-derived NK cells can be delivered off-the-shelf and administered without patient matching,” said Wayne Chu, M.D., Vice President of Clinical Development of Fate Therapeutics.

  • Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment?
    Simply Wall St.

    Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 27, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire

    Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 14, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire

    Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting

    FT596 Selected by ASH for Feature at “CAR-T and Beyond” Press Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer.

  • Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

    Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.26% and 26.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2019. “We achieved several significant clinical milestones over the past three months including treating the first patients with FT516, the first-ever engineered iPSC-derived cellular immunotherapy, and securing FDA clearance to initiate clinical investigation of FT596, the first-ever cellular immunotherapy engineered to express three active anti-tumor modalities.

  • GlobeNewswire

    Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 29, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Hedge Funds Have Never Been More Bullish On Fate Therapeutics Inc (FATE)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Fate Therapeutics Inc (FATE)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • What Kind Of Shareholder Owns Most Fate Therapeutics, Inc. (NASDAQ:FATE) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Fate Therapeutics, Inc. (NASDAQ:FATE) Stock?

    The big shareholder groups in Fate Therapeutics, Inc. (NASDAQ:FATE) have power over the company. Insiders often own a...